Payment overview · 2025
General Payments
$274.23
9 reported records · 7 companies
Healthcare provider profile · identity verified
Nelson Mane, MD, DC
Allopathic & Osteopathic Physicians|Internal Medicine · TAMPA, FL · NPI 1568520971
Verified facts
What the public records show
CMS Open Payments records show Nelson Mane, MD, DC received $274.23 in general payments during 2025 across 9 reported records.
Amgen Inc. accounted for 54.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 217 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $148.59 | 54.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.97 | 8.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $21.66 | 7.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.24 | 7.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.03 | 7.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.68 | 7.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.06 | 6.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $274.23 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $148.59 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.97 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $23.59 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $21.66 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $21.24 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.03 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.68 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 217 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 120 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
120 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
120 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
217 | 66 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 777 | 246 |
| Levothyroxine Sodium | Levothyroxine Sodium | 692 | 202 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 561 | 200 |
| Amlodipine Besylate | Amlodipine Besylate | 555 | 182 |
| Lisinopril | Lisinopril | 422 | 132 |
| Losartan Potassium | Losartan Potassium | 399 | 139 |
| Gabapentin | Gabapentin | 294 | 89 |
| Metoprolol Tartrate | Metoprolol Tartrate | 289 | 94 |
| Metformin Hcl | Metformin Hcl | 288 | 98 |
| Trazodone Hcl | Trazodone Hcl | 264 | 77 |
| Alprazolam | Alprazolam | 252 | 75 |
| Omeprazole | Omeprazole | 249 | 83 |
| Furosemide | Furosemide | 231 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 230 | 75 |
| Eliquis | Apixaban | 217 | 66 |
| Clopidogrel | Clopidogrel Bisulfate | 211 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 205 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 200 | 76 |
| Famotidine | Famotidine | 199 | 69 |
| Simvastatin | Simvastatin | 188 | 59 |
| Prednisone | Prednisone | 168 | 125 |
| Montelukast Sodium | Montelukast Sodium | 165 | 57 |
| Sertraline Hcl | Sertraline Hcl | 159 | 49 |
| Donepezil Hcl | Donepezil Hcl | 138 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 133 | 43 |
| Mirtazapine | Mirtazapine | 132 | 30 |
| Glimepiride | Glimepiride | 129 | 41 |
| Ezetimibe | Ezetimibe | 127 | 50 |
| Allopurinol | Allopurinol | 126 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 125 | 56 |
| Meloxicam | Meloxicam | 122 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 121 | 42 |
| Jardiance | Empagliflozin | 120 | 33 |
| Tramadol Hcl | Tramadol Hcl | 115 | 34 |
| Pioglitazone Hcl | Pioglitazone Hcl | 113 | 33 |
| Azithromycin | Azithromycin | 110 | 100 |
| Potassium Chloride | Potassium Chloride | 110 | 30 |
| Farxiga | Dapagliflozin Propanediol | 109 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 106 | 33 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 100 | 19 |
| Carvedilol | Carvedilol | 98 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 40 |
| Lorazepam | Lorazepam | 92 | 36 |
| Atenolol | Atenolol | 85 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 83 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 80 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 77 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 77 | 19 |
| Spironolactone | Spironolactone | 75 | 27 |
| Xarelto | Rivaroxaban | 71 | 12 |
| Buspirone Hcl | Buspirone Hcl | 65 | 25 |
| Levetiracetam | Levetiracetam | 65 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 27 |
| Celecoxib | Celecoxib | 62 | 27 |
| Finasteride | Finasteride | 62 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 61 | 52 |
| Synthroid | Levothyroxine Sodium | 59 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 56 | 27 |
| Alendronate Sodium | Alendronate Sodium | 55 | 20 |
| Bupropion Xl | Bupropion Hcl | 55 | 17 |
| Bumetanide | Bumetanide | 52 | 15 |
| Divalproex Sodium | Divalproex Sodium | 51 | suppressed |
| Fenofibrate | Fenofibrate | 51 | 19 |
| Metformin Hcl Er | Metformin Hcl | 51 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 20 |
| Glipizide | Glipizide | 50 | 17 |
| Terazosin Hcl | Terazosin Hcl | 50 | 21 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 49 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 48 | 13 |
| Procrit | Epoetin Alfa | 48 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 46 | 41 |
| Warfarin Sodium | Warfarin Sodium | 46 | suppressed |
| Entresto | Sacubitril/Valsartan | 45 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 45 | 11 |
| Temazepam | Temazepam | 44 | 14 |
| Methocarbamol | Methocarbamol | 43 | 25 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 42 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 41 | 17 |
| Memantine Hcl | Memantine Hcl | 40 | 12 |
| Clonidine Hcl | Clonidine Hcl | 39 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 30 |
| Aripiprazole | Aripiprazole | 38 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 38 | 14 |
| Clonazepam | Clonazepam | 35 | 13 |
| Enalapril Maleate | Enalapril Maleate | 35 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | 11 |
| Baclofen | Baclofen | 34 | suppressed |
| Pregabalin | Pregabalin | 34 | suppressed |
| Fluconazole | Fluconazole | 33 | 22 |
| Januvia | Sitagliptin Phosphate | 33 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 25 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 32 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | 12 |
| Latanoprost | Latanoprost | 31 | suppressed |
| Dexamethasone | Dexamethasone | 30 | 30 |
| Diazepam | Diazepam | 30 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Telmisartan | Telmisartan | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | 11 |
| Ozempic | Semaglutide | 29 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Cefdinir | Cefdinir | 27 | 19 |
| Morphine Sulfate Er | Morphine Sulfate | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | 15 |
| Ramipril | Ramipril | 26 | 11 |
| Ranolazine Er | Ranolazine | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 18 |
| Felbamate | Felbamate | 25 | suppressed |
| Klor-Con 10 | Potassium Chloride | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 14 |
| Methotrexate | Methotrexate Sodium | 24 | suppressed |
| Nystatin | Nystatin | 24 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Oxycontin | Oxycodone Hcl | 22 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | 12 |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Levemir | Insulin Detemir | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | 12 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Lactulose | Lactulose | 13 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 11 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $274.23 · 9 records | Amgen Inc. | ELIQUIS, JARDIANCE, LEQVIO, MOUNJARO, OTEZLA, REPATHA, REXULTI, Veozah | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error